Background {#Sec1}
==========

Asthma is a chronic airway inflammation, characterized by variable airway obstruction and reduced lung function, and leading to wheezing and shortness of breath \[[@CR1]\]. It is described as a complex disease arising from the contribution of multiple genetic and environmental factors \[[@CR2], [@CR3]\], affecting more than 300 million people worldwide, with increased prevalence in developed societies \[[@CR4]\].

In Portugal, 7.83% of the population is affected by clinical asthma and 8.72% by wheezing symptoms \[[@CR5]\]. Within Portugal, the island of Madeira has a high prevalence of the disease, as active asthma (presence of symptoms during the last 12 months) affects 14.6%, and atopy (positive reaction to skin prick tests (SPT) to common aeroallergens and the presence of specific IgE) affects 54% of the population \[[@CR6]\].

Given the high prevalence of asthma in the Madeira population \[[@CR6]\], determining the population's genetic background is an essential first step towards understanding the mechanisms of the disease. In previous work \[[@CR7]\] we showed that both *IL4-590* and *IL4-RP2* are useful genetic markers to detect asthma predisposition in the Madeira population. Investigating a larger number of genes is important because many genes with small effects, rather than just a few with strong effects, contribute to the disease risk \[[@CR8]\]. A useful clustering of asthma susceptibility genes has been proposed \[[@CR9]\]: i) triggers of the immune response (such as *CD14, IL10*, *STAT3*, MHC class II molecules*)*; ii) regulators of the T helper 2 (Th2) differentiation (*IL12B*, *IL4*, *IL13*, *STAT6, IL4RA)*; iii) associated with epithelial biology (*CCL5*, *FLG*, *SPINK5, GSDML*) and iv) linked to lung function, airway remodeling and asthma severity (*ADRB2, ADAM33*, *DPP10*, *PHF11).*

Here we extend our analysis in four important ways, to consider i) 6 additional polymorphisms, namely *IL13-c.144 G/A, ADRB2-c.16 A/G, ADAM33-V4 C/G, ADAM33-S1 c.710 G/A, GSDML-236 C/T* and *STAT6-21 C/T* (guided by a literature review summarized in Table [1](#Tab1){ref-type="table"}), ii) the asthma persistence and severity classes according to GINA guidelines, iii) the most common allergens in the island and iv) the FEV~1~/FVC lung function indexes. Therefore, this work contributes to the analysis of the association of the above polymorphisms to asthma susceptibility and severity, FEV~1~/FVC indexes and sensitization profiles, in the Madeira population.Table 1**Selected studies previously reporting association of the studied SNPs and asthma**GenePolymorphismdbSNP rs ref (NCBI)Chromosome locationAlleles (ancestral:derived)References*IL13c.144*Gln/Argrs205415q31 exon 4G \> A\[[@CR10]--[@CR16]\]*IL4590*rs22432505q31 promoterC \> T\[[@CR17]--[@CR23]\]*IL4RP2*-5q31 intron 2253 \> 183(del)\[[@CR24]\]*ADRB2c.16*Arg/Glyrs10427135q31 exonA \> G\[[@CR25], [@CR26]\]*ADAM33V4*rs278709420p13 3'UTRC \> G\[[@CR27]--[@CR30]\]*ADAM33S1 c.710*Val/Ilers391839620p13 exon 19G \> A\[[@CR27]\]*GSDML236*rs721638917q21 intron 1C \> T\[[@CR31]--[@CR39]\]*STAT621*rs32401112q13-24 intron 2C \> T\[[@CR19], [@CR40]--[@CR44]\]

Results {#Sec2}
=======

Demographic and clinical characterization of the asthmatics {#Sec3}
-----------------------------------------------------------

The demographic and clinical characterization of the asthmatic population analysed in this study are shown in Table [2](#Tab2){ref-type="table"}. The patients' mean age was 13.6 ± 4.3 years old, with 59.2% males. None of the asthma persistence or severity phenotypes was found sub-structured by the male-to-female ratio. The FEV~1~ and FVC indexes were significantly different between mild persistent and moderate-severe persistent asthma (Mean FEV~1~ t = 2.732, p-value = 0.008; FVC Mann--Whitney U = 456.0, p-value = 0.025).Table 2**Clinical characterization of the asthmatics study population**Study sample setOverall asthmaIntermittent asthmaPersistent asthmaMildModerate-severep-valueSample size (n,%)98 (100.0)24 (24.5)74 (75.5)44 (59.9)30 (40.5)Male/Female (%)59.2/40.862.5/37.558.1/41.954.5/45.563.3/36.7Mean age (years + -s.d.)13.6 + -4.314.1 + -3.513.4 + - 4.514.3 + -4.612.0 + - 4.1Mean FEV~1~ (%)96.9 + -14.798.5 + -16.396.4 + -14.2**99.9 + -10.791.2 + - 17.10.008**Mean FVC (%)95.0 + -12.897.4 + -12.194.3 + -13.0**97.3 + -9.989.8 + -15.60.025**Asthma classification according to GINA \[[@CR75]\].A Shapiro-Wilk test showed that FEV~1~ is normally distributed (p \> 0.05) while FVC is not (p = 0.008). Thus, a t-test was used for the analysis of FEV~1~ while a Mann--Whitney test was used for FVC. Statistically significant p-values were found for comparisons between mild persistent and moderate-severe persistent asthma, denoted in bold.

Although persistent asthmatics were found more frequently sensitized to both cat and dog allergen than intermittent asthmatics (Additional file [1](#MOESM1){ref-type="media"}) no significant differences were observed for SPT positivity or degree of sensitization to the most common allergens in the island, namely dust and storage mites mix fungi, indoor fungi, cat or dog.

SNP association to asthma risk and severity {#Sec4}
-------------------------------------------

The genotypic and allelic frequencies of each SNP among asthma subgroups and population reference set are described in Table [3](#Tab3){ref-type="table"} and Additional file [2](#MOESM2){ref-type="media"}, respectively. The genotypic distribution of SNPs in controls reflects previously published data on other European and Mediterranean populations \[[@CR45], [@CR46]\]. All SNP polymorphisms were found to be in HWE, except for *STAT6-21 locus* in mild persistent asthma (p-value = 0.038). Nevertheless, this SNP was considered in the analysis under a more stringent p-value cut-off of 0.01, since a slight deviation from HWE is allowed for SNPs linked to disease status \[[@CR47]\].Table 3**SNP genotypic frequencies for the Madeira reference set and asthmatics study population**SNP genotypesStudy sample setMadeira reference setOverall asthmaIntermittent asthmaPersistent asthmaMildModerate-severe105^a^9824744430*IL4-590 C/T*CC0.8000.6430.7080.6220.7050.500CT0.1910.3270.2500.3510.2950.433TT0.0090.0310.0420.02700.067**p-value0.0090.0060.002OR (95%CI)2.222 (1.191-4.146)2.433 (1.264-4.717)4.000 (1.701-9.434)***IL4-RP2 253/183*2532530.8180.6940.7920.6620.7500.5331832530.1550.2760.1670.3110.2500.4001831830.0270.0310.0420.02700.067**p-value0.0270.0130.002OR (95%CI)1.984 (1.040 -3.788)2.296 (1.159 -4.547)3.938 (1.657- 9.357)***IL13-c.144 G/A*GG0.6760.7040.6250.7300.7730.667GA0.3050.2670.3330.2570.2050.333AA0.0190.0200.0420.0140.0230*ADRB2-c.16 A/G*AA0.1810.1940.2500.1760.2500.067AG0.4570.4800.4580.4860.3640.667GG0.3620.3270.2920.3380.3860.267**p-value0.010\*OR (95%CI)3.500 (1.318-9.293)***ADAM33-V4 C/G*GG0.0290.01000.0140.0230CG0.2090.2350.2920.2160.1820.267CC0.7620.7550.7080.7700.7950.733*ADAM33-S1c.710* *G/A* GG0.9050.9290.9170.9320.9320.933GA0.0950.0710.0830.0680.0680.067AA000000*GSDML-236 C/T*CC0.1710.1630.1670.1620.1360.200CT0.4670.4690.5000.4590.3640.600TT0.3620.3670.3330.3780.5000.200**p-value0.008\*\*OR (95%CI)0.250 (0.086-0.730)***STAT6-21 C/T* ^b^CC0.4280.4490.4170.4590.5230.367CT0.4860.4180.4580.4050.2950.567TT0.0860.1330.1250.1350.1820.067a) Except for *IL4-590* and *IL4-RP2* (n = 110);b) Polymorphism not in HWE for mild asthma (p-value = 0.038).χ^2^ (or Fisher's exact test when appropriate) significant p-values and OR (95%CI), using the Madeira reference set as a control, are shown in bold (dominant model).\* Heterozygote model, significant p-values and OR (95%CI) for comparison between mild persistent and moderate-severe persistent; Dominant model, Fisher's exact test p-value = 0.038, OR (95%CI) 4.667 (0.953-22.851); \*\* Recessive model, significant p-values and OR (95%CI) for comparison between mild persistent and moderate-severe persistent; Heterozygote model: Fisher's exact test p-value = 0.039, OR 2.625 (1.011-6.817).

Table [3](#Tab3){ref-type="table"} shows significant effects for the genotypes *IL4-590\*CT/TT*, *IL4-RP2\*183253*/*183183*, *ADRB2-c.16\*AG/AA*, and *GSDML-236\*TT*. Specifically, the *IL4-590\*CT/TT* genotypes were significantly more frequent in asthma patients (35.8% *vs.* 20.0%, χ^2^ p-value = 0.009; OR 2.222, 95% CI 1.191-4.146), persistent asthma (37.8% *vs.* 20.0%; χ^2^ p-value = 0.006; OR 2.433, 95% CI 1.264-4.717), and moderate-severe asthma *vs.* the reference set (20% *vs.* 50.0%; χ^2^ p-value = 0.002; OR 4.000, 95% CI 1.701-9.434). Genotypes *IL4-RP2\*183253*/*183183* were significantly more frequent in asthma patients (30.7% *vs.* 18.2%; χ^2^ p-value = 0.027; OR 1.984, 95% CI 1.040-3.788), in persistent asthma (33.8% *vs.* 18.2%; χ^2^ p-value = 0.013; OR 2.296, 95% CI 1.159-4.547), and in the moderate-severe asthma *vs.* the reference set (46.7% *vs.* 18.2%; χ^2^ p-value = 0.002; OR 3.938, 95% CI 1.657-9.357). *ADRB2-c.16\*AG* was significantly more frequent in moderate-severe asthma *vs.* mild asthma (66.7% *vs.* 36.4%, p-value = 0.010, OR 3.500, 95% CI 1.318-9.293) while *GSDML-236\*TT* displays a significant opposite trend (20.0% and 50.0%, respectively in moderate-severe and mild asthma; χ^2^ p-value = 0.008, 0R 0.250 95% CI 0.086-0.730).

The results described above are corroborated by the allelic counts (Additional file [2](#MOESM2){ref-type="media"}) of *IL4-590\*T,* which are significantly higher in asthma patients (19.4%; χ^2^ p-value = 0.010, OR 2.060, 95% CI 1.178-3.601), in persistent asthma (20.3% χ^2^ p-value = 0.009, OR 2.178 95% CI 1.208-3.925), and in moderate-severe (28.3%, χ^2^ p-value = 4.514\*10^-4^, OR 3.386 95% CI 1.668-6.877) *vs.* the reference set (10.5%). Similarly, the allelic counts of *IL4-RP2\*183* were significantly higher in moderate-severe *vs.* the reference set (26.7% *vs.* 10.5%; χ^2^ p-value = 0.001, OR 3.115 95% CI 1.521-6.379).

SNP association to FEV~1~ and FVC {#Sec5}
---------------------------------

Table [4](#Tab4){ref-type="table"} shows the association analysis of SNP genotypes with the FEV~1~ and FVC indexes. Significant differences were found for mean FEV~1~ distribution among *IL4-590\*C/T* genotypes (F = 3.982, p-value = 0.024), with *IL4-590\*CT/TT* patients exhibiting a significantly lower FEV~1~ values when compared to *IL4-590\*CC* homozygotes patients (t = 2.797, p-value = 0.006). Similarly, a significantly lower FEV~1~ index was found amongst patients with *IL4-RP2\*183253/183183* when compared to *IL4-RP2\*253253* homozygotes (t = 2.974, p-value = 0.004).Table 4**Mean FEV** ~**1**~ **and FVC indexes across SNP genotypes**SNP genotypesLung function indexesFEV ~1~ (mean +/-s.d.)FVC (mean+/-s.d.)n9898*IL13-c.144 G/A*GG98.42 + -13.9596.33 + -11.88GA93.44 + -16.5892.15 + -14.79AA92.50 + -7.7889.50 + -12.02*IL4-590 C/T*CC99.92 + -14.2896.87 + -11.28CT91.69 + -14.4192.13 + -14.79TT90.00 + -12.0087.67 + 16.04**F p-value0.024Dominant model CT/TT vs CC0.006***IL4-RP2 253/183*25325399.75 + -14.1597.07 + -11.3418325390.59 + -14.5290.74 + -14.8918318390.00 + -12.0087.67 + -16.04**F p-value0.015Dominant model 183253/183183 vs 2532530.004***ADRB2-c.16 A/G*AA95.16 + -19.7991.74 + -16.20AG95.91 + -12.8394.91 + -11.95GG99.47 + -13.9497.19 + -11.62*ADAM33-V4 C/G*GG99.00 + -0 ^c^98.00 + -0^c^CG94.65 + -15.6694.26 + -10.19CC97.61 + -14.5395.24 + -13.61*ADAM33-S1c.710 G/A*GG97.13 + -14.8195.22 + -13.05GA94.29 + -13.9692.71 + -8.92AA\--*GSDML-236 C/T*CC99.13 + -13.2094.25 + -12.07CT96.30 + -17.4894.13 + -14.34TT96.75 + -11.3496.56 + -11.04*STAT6-21 C/T*CC97.34 + -15.7495.00 + -14.28CT96.49 + -13.5294.24 + -11.73TT96.92 + -15.7397.69 + -11.01^c^ n = 1.A Shapiro-Wilkoxon test showed that FEV~1~ is normally distributed (p \> 0.05) while FVC is not (p = 0.008). Thus, ANOVA was used for FEV~1~ analysis while a Kruskal-Wallis test was used for FVC.

SNP association to SPT {#Sec6}
----------------------

Despite not associated to SPT positivity, some of the studied SNPs relate to the sensitization degree (Table [5](#Tab5){ref-type="table"}). *ADAM33-V4\*CC* relates to house dust mite (*Dermatophagoides pteronyssinus* χ^2^ p-value = 0.016, OR 1.325, 95% CI 1.070-1.641 and *Blomia tropicalis* χ^2^ p-value = 0.047, OR 1.355, 95% CI 1.131-1.622). *STAT6-21\*TT* is associated to the degree of sensitization for storage mite (χ^2^ p-value = 0.003, OR 7.778, 95% CI 1.682- 35.962).Table 5**Skin prick tests positivity across SNP genotypes***Allergen panel*SNP genotypes*ADAM33-V4 C/G*nGGCGCCp-valueOR (95% CI)*Dermatophagoides pteronyssinus*(-)230.0430.3480.609(+)7400.2030.797\< 10 mm4400.2950.705≥ 10 mm3000.0670.933**0.0161.325 (1.070-1.641)***Blomia tropicalis*(-)430.0230.2790.698(+)5400.2040.796\< 10 mm4200.2620.738≥ 10 mm12001.00**0.0471.355 (1.131-1.622)***STAT6-21 C/T*CCCTTT*Storage mites*(-)530.3960.4720.132(+)440.5000.3640.236\< 10 mm350.5140.4290.057≥ 10 mm90.4440.1110.444**0.003\*7.778 (1.682-35.962)**Only significant associations are reported, in bold.Storage mites: *Lepidoglyphus destructor*, *Glycifagus domesticus*, *Acarus siro*, *Euroglyphus maynei* and *Tyrophagus putrescentiae* allergens, classified as ≥ 10 mm if at least one test resulted in wheal diameter ≥ 10 mm.\*Recessive model.

SNP haplotypes and epistasis association to asthma risk {#Sec7}
-------------------------------------------------------

Table [6](#Tab6){ref-type="table"} shows the haplotype frequencies for SNPs at the 5q31 and 20p13 chromosomal regions. At the 5q31, we highlight *IL4-590/IL4-RP2\* T183* frequency, which is significantly lower in the reference set (8.8%) than overall asthma (16.8%, p-value = 0.019), persistent asthma (18.2%, p-value = 0.011), and moderate-severe asthma (26.7%, p-value = 3×10^-4^). In addition, this same haplotype was more common in moderate-severe *vs.* mild asthma (26.7% *vs*. 12.5%, p-value = 0.029). In fact, every haplotype found to associate with the risk of asthma includes either *IL4-590 C/T* or *IL4-RP2183/253* or both. Compared to the reference set, the most significant combinations are i) overall asthma *IL13c.144/IL4-590\*GT* (p-value = 0.018); ii) persistent asthma *IL13c.144/IL4-590\*GT* (p-value = 0.010) and *iii)* moderate-severe asthma *IL4-590/IL4-RP2\*T183* (p-value = 3x10^-4^). *IL13c.144/IL4-RP2\*A183* is also more frequently found in moderate-severe asthma than in mild asthma (p-value = 0.017).Table 6**SNP haplotype frequencies in the Madeira reference set and the asthmatics study population**Haplotype blockStudy sample setMadeira reference setOverall asthmaIntermittent asthmaPersistent asthmaMildModerate-severe105^a^9824744430*IL4-590/ IL4-RP2*T1830.088**0.168 (0.019)**0.125**0.182 (0.011)**0.125**0.267 (3x10** ^**-4**^ **/0.029\*)**C2530.8940.8060.8330.7970.852**0.717 (0.004/0.044\*)***IL4-590 /ADRB2-c.16*TA0.018**0.058 (0.037)**0.064**0.055 (0.048)**0.031**0.085 (0.009)**TG0.0920.1360.1020.1480.117**0.199 (0.023)***IL4-RP2/ADRB2-c.16*183A0.0250.0570.0590.0560.032**0.089 (0.026)**183G0.0840.1110.0660.1270.093**0.178 (0.037)***IL13-c.144/ IL4-590*GT0.064**0.134 (0.018)**0.098**0.146 (0.010)**0.128**0.166 (0.010)**AT0.0460.0600.0680.0570.020**0.110 (0.020\*)***IL13-c.144/ IL4-RP2*G1830.0590.1060.052**0.124 (0.033)**0.105**0.147 (0.022)**A1830.0500.0630.0730.0590.021**0.114 (0.017\*)***IL13-c.144/ IL4-590/ IL4-RP2*GT1830.051**0.107 (0.041)**0.054**0.125 (0.016)**0.105**0.148 (0.009)**AT1830.0400.0620.0710.0580.020**0.119 (0.024/0.018\*)***IL4-590/ IL4-RP2/ ADRB2-c.16*T183A0.016**0.055 (0.038)**0.052**0.053 (0.045)**0.030**0.082 (0.008)**T183G0.0730.1130.0670.1290.095**0.184 (0.013)**Haplotypes denoting significant differences are shown in bold, with respective p-values within parentheses. Significant p-values, using Madeira reference set as a control, are shown within parentheses; \* significant p-values for comparison between mild persistent and moderate-severe persistent.

Epistatic interactions between pairs of SNPs between all asthma subgroups were tested, revealing significant epistasis for *loci IL4-590* and *STAT6-21* in moderate-to-severe compared to intermittent asthma (p-value = 0.044) and *IL13-c.144* and *ADAM33-V4* between persistent asthma and the Madeira reference set (p-value = 0.035).

TDT association analysis {#Sec8}
------------------------

The TDT analysis in Table [7](#Tab7){ref-type="table"} suggests that the *ADAM33-V4\*C* allele is significantly over transmitted to offsprings in overall asthma (ratio 27/15 of transmitted/non-transmitted; McNemar χ^2^ 3.429, p-value = 0.044, OR 1.800, 95% CI 0.956-3.384), in persistent asthma (ratio 22/9 of transmitted/non-transmitted; McNemar χ^2^ 5.452, p-value = 0.015 OR 2.444, 95% CI 1.126-5.309), and in mild asthma (ratio 16/4 of transmitted/non-transmitted; McNemar χ^2^ 7.200 p-value = 0.006 OR 4.000, 95% CI 1.337-11.965). *IL4-590\*T* and *IL4-RP2\*183* alleles were found to be significantly over transmitted only amongst moderate-severe offspring asthma (ratio 15/6 of transmitted/non-transmitted; McNemar χ^2^ 3.857, p-value = 0.039 OR 2.500, 95% CI 0.970-6.443 and ratio 14/4 of transmitted/non-transmitted; McNemar χ^2^ 5.556, p-value = 0.015 OR 3.500, 95% CI 1.152-10.663, respectively).Table 7**TDT analysis in family trios for SNP association with asthma**SNP alleleValid trios (n)TDT-test valueTDT p-valueOR (95% CI)**Overall asthma***ADAM33-V4\*C*413.429**0.044**1.800 (0.956-3.384)**Persistent asthma***ADAM33-V4\*C*305.452**0.0152.444 (1.126-5.309)Mild asthma***ADAM33-V4\*C*197.200**0.0064.000 (1.337-11.965)Moderate-severe asthma***IL4-590\*T*193.857**0.039**2.500 (0.970-6.443)*IL4-RP2\*183*175.556**0.0153.500 (1.152-10.633)**Only significant associations are reported, in bold.

Discussion {#Sec9}
==========

In the asthmatic patients studied, 24.5% are classified as intermittent asthmatics while the remaining are persistent asthmatics (of which 40.5% show moderate-severe forms of the disease). The significant differences we observed for FEV~1~ and FVC indexes denote these as reliable indicators for disease severity, as previous stated by a number of studies \[[@CR48]--[@CR50]\].

SNP *IL4-590 C/T* has been repeatedly associated to asthma in several population backgrounds \[[@CR17]--[@CR22]\] and the results of this study in the Madeira island population are no exception (previously reported by our research team \[[@CR7]\]. Our findings show that *IL4-590\*CT/TT* genotypes associate to a 2.2-fold risk for asthma (2.4-fold for overall persistent asthma and 4-fold for moderate-severe persistent asthma) while *IL4-590\*T* allele represents a 2-fold risk for asthma (2.2-fold for persistent asthma and 3.4-fold for moderate-severe asthma), compared to individuals harbouring other *IL4-590 C/T* genotypes or allele. Our findings also indicate that *IL4-RP2\*253183/183183* genotypes translate into a 2-fold increased risk for asthma (2.3-fold and 2.9-fold respectively for persistent and moderate-severe persistent asthma), in particular *IL4-RP2\*183* allele (3.1-fold risk for moderate-severe persistent asthma). This SNP has been implicated in childhood asthma in a Chinese population, where authors suggest a link between the allele and higher expression of IL4 in asthma \[[@CR24]\]. The findings for *IL4* SNPs are further corroborated by the association of the risk genotypes to worse lung function, namely lower FEV~1~ index. Genotype *IL4-590\*TT* has been previously associated with lower FEV~1~ index, used as a measure for asthma severity, in a population of white asthmatic subjects \[[@CR51]\].

IL4 is a key cytokine in IgE production via Th2 pathway \[[@CR52]\], which has been previously shown to play an important role in asthma pathogenesis \[[@CR53]\]. Its serous levels are significantly higher in steroid-naive asthmatic children and severe forms of asthma when compared to healthy control groups \[[@CR54], [@CR55]\]. From a functional perspective, it is not surprising that *IL4* SNPs may regulate its transcription rates: allele *IL4-590\*T* allows an extra binding site for the nuclear factor of activated T-cells (NFAT) at *IL4* promoter, leading to a 3-fold higher transcription rate \[[@CR23]\]; haplotypes with *IL4-RP2\*183* and SNPs within *IL4* promoter account for high IL4 expression \[[@CR56]\].

The case--control associations of *IL4-590\*T* and *IL4-RP2\*183* to moderate-severe persistent asthma are further corroborated by TDT analysis (2.5 and 3.5-fold increased risk respectively). TDT is a family-based test robust against population stratification \[[@CR57], [@CR58]\] defined as the presence of multiple subgroups with distinct allele frequencies within a population \[[@CR59]\]. Although stratification is mostly noticed in recent history of admixture \[[@CR60]\], we cannot disregard the considerable sub-Saharan and northern African proportion in the Madeira genetic background, due to the North Atlantic slavetrade on the 16^th^-19^th^ centuries and previously confirmed by Y-chromosome \[[@CR61]\] and mtDNA studies \[[@CR62]\].

Previous studies have related *ADRB2-c.16\*GG* to asthma onset and severity \[[@CR25], [@CR26]\]. Conversely, our data suggest heterozygous *ADRB2-c.16\*AG* as 3.5-fold risk genotype for moderate-severe asthma. In the absence of functional studies, we can only hypothesize that heterodimeric ADRB2 receptors on the bronchial smooth muscle may be less stable or bind to a more restricted scope of products than homodimeric receptors, therefore enhancing more severe forms of asthma. However, the high heterozygosity for *ADRB2-c.16* is found not only in patient's subgroups but also in the Madeira reference set and other population sets \[[@CR63]--[@CR65]\]. Even though it deserves more attention, this may indicate heterozygote advantage for this SNP or other in linkage disequilibrium, in a metabolic pathway that may or may not relate to asthma pathogenesis. Other examples of heterozygote advantage in *ADRB2* exist, such as *ADRB2-c.27\*CG* that is protective against lung function decline \[[@CR66]\] and accounts for a decreased risk of asthma \[[@CR67]\].

In our data, *GSDML-236\*TT* genotype is found to be a protective for asthma severity, with a 4-fold significantly lower frequency in moderate-severe asthma, as opposed to mild. *GSDML-236C/T* polymorphism has been related to asthma predisposition, severity and/or asthma-related phenotypes in a number of studies \[[@CR31]--[@CR39]\]. However, our results are in contrast to certain previous studies, which suggest this genotype is a genetic risk factor for the disease severity \[[@CR32], [@CR35], [@CR37], [@CR38]\]. The *GSDML* encodes for gasdermin B protein expressed in epithelial barrier function and skin differentiation, influencing the expression of the neighbouring gene *ORMDL3* and thus contributing to asthma susceptibility \[[@CR34]\].

The case--control association in our dataset does not support the influence of *ADAM33-V4C/G* or *ADAM33-S1c.710G/A* in asthma, contrary to some previous work \[[@CR27]--[@CR30]\] and consistent with other studies \[[@CR68]\]. *ADAM33-V4\*C* allele was nevertheless marginally over transmitted to Madeira asthmatics, as suggested by TDT analysis (1.8-fold risk for overall asthma, 2.4-fold risk for persistent asthma and 4-fold risk for mild asthma). A similar trend of association was seen in Caucasian children with asthma and bronchial responsiveness (p-value = 0.0959) \[[@CR27]\]. Located at 3'-UTR, *ADAM33-V4C/G* SNP may influence the expression of its encoded desintegrin and metallopeptidase domain 33 in airway smooth muscle and lung fibroblasts \[[@CR27], [@CR69], [@CR70]\] thus playing a role on airway remodeling and bronchial responsiveness \[[@CR27], [@CR71]\]. In addition, our study associates *ADAM33-V4\*CC* to a wheal size ≥ 10 mm both in *Dermatophagoides pteronyssinus* and *Blomia tropicalis*, in accordance with a previous study relating *ADAM33-V4\*CC* to high levels of IgE against *Blomia tropicalis* (Z score: 2.089, p = 0.03) \[[@CR72]\].

No significant association with the disease risk was detected for *STAT6-21C/T,* similar to the analysis in \[[@CR73]\] but contrary to other studies \[[@CR19], [@CR40]--[@CR44]\]. However, *STAT6-21\*TT* is overrepresented in asthmatics with a ≥10 mm wheal size reaction to storage mites and shows a significant epistatic interaction with *IL4-590C/T* between moderate-severe persistent and intermittent asthma. The enhanced allergic response is not unexpected since STAT6 is a signal transducer and activator of transcription enrolled in the regulation of IgE expression \[[@CR40], [@CR52], [@CR74]\] whose *STAT6-21\*T* allele promotes higher levels of IgE \[[@CR19]\].

Finally, the haplotype analysis was significant for SNPs at 5q31, namely *IL4-590\*T* and *IL4-RP2\*183* in overall asthma, persistent asthma and moderate-severe persistent asthma. Haplotypes of *IL4-RP2\*183* and SNPs within the promoter of *IL4* have been found to account for high IL4 expression \[[@CR56]\]. Our results also indicate the synergistic effect of *IL13c.144\*G* and *ADRB2\*G* with either *IL4-590\*T* or *IL4-RP2\*183* or both for the onset of asthma persistent phenotypes. Nevertheless, their combination equals or slightly lowers the statistical significance of *IL4-590/IL4-RP2\*T183* haplotype in the same classes.

Conclusion {#Sec10}
==========

In conclusion, this study has replicated previously reported genetic associations and brought light to new associations of polymorphisms, individually or in haplotype, to asthma susceptibility, persistence and/or severity in the Madeira island population. *IL4-590C/T* and *IL4-RP2253/183* seem to play an important role in the development of the disease, especially its moderate-severe persistent forms, as demonstrated by allele and haplotype case--control tests, TDT analysis, and significantly poorer FEV~1~ index. *GSDML\*CT/TT* and *ADRB2c.16\*AG* are found to predict asthma severity in case--control association, respectively as risk and protective factors for moderate-severe forms. *ADAM33-V4\*C* and *STAT-21\*TT* seem to enhance the allergic response to *Dermatophagoides pteronyssinus* and *Blomia tropicalis* and to storages mites, respectively, and the first is further highlighted by TDT analysis as a risk factor for mild persistent asthma. The combined genotyping of *IL4-590C/T, IL4-RP2-253/183, GSDML-236C/T* and *ADAM33-V4C/G* could be of clinical relevance in ascertaining the risk of asthma onset and/or its persistence and severity, thus helping to define appropriate strategies for asthma healthcare in this island.

Methods {#Sec11}
=======

Participants {#Sec12}
------------

A sample of 98 atopic asthmatics, aged between 6 and 25 years old, and their parents (fathers n = 88 and mothers n = 96) were recruited at the Immunoalergology Unit, Dr. Nélio Mendonça Hospital, in Funchal, Madeira. For all participants, the last three generations of ancestors were born and lived in Madeira island. The diagnosis of asthma was based on clinical criteria associated with lung function and the SPT. For the epidemiologic characterization we deployed the ISAAC questionnaire to the asthmatic population and their parents. Following the GINA guidelines \[[@CR75]\], pattern and frequency of symptoms associated with lung function were used to classify asthma into intermittent (n = 24) and persistent (n = 74), and the severity in persistent asthma was further classified as mild (n = 44), moderate (n = 26) and severe (n = 4). Given the small number of patients, the moderate and severe subgroups were merged. Asthma induced by exercise and associated to aspirin was excluded.

Ethics statement {#Sec13}
----------------

The study had the approval of the Ethics Committee of Dr. Nélio Mendonça Hospital and the informed consent of the participants.

Allergy profile {#Sec14}
---------------

The SPT was tested for an optimized battery with the most common aeroallergens in this island: house dust mite (*Dermatophagoides pteronyssinus, Blomia tropicalis*)*;* storage mite (*Lepidoglyphus destructor, Glycyphagus domesticus, Acarus siro, Euroglyphus maynei, Tyrophagus putrescentiae*)*;* Mix fungi (Fungus I*,* Fungus II)*;* indoor fungi (*Aspergillus fumigatus, Mucor sp.*) and cat and dog. STP results were interpreted according to mean wheal size: positive ≥3 mm, sensitization degree ≤10 mm or ≥10 mm.

DNA extraction and genotyping {#Sec15}
-----------------------------

Patients' blood samples were collected by venipuncture in 8 ml EDTA blood collection tubes and their DNA was extracted by salting-out method (adapted from \[[@CR76]\]). Their parents contributed with saliva samples, collected in Oragene•DNA (OG-250) kits (Oragene). The DNA extraction followed the manufacturer's instructions.

A sample of 110 unrelated individuals, whose ancestry was of local origin for the last three generations, was obtained from the Blood Sample Bank of Human Genetics Laboratory (LGH) and their DNA extraction was performed by a standard phenol-chloroform protocol (adapted from \[[@CR77]\]). These constitute the Madeira population reference sample set, although their disease status is unknown. The reference sample set was not matched to the patient's group to uphold a less biased study design. Each SNP (Table [1](#Tab1){ref-type="table"}) was analysed by TaqMan real-time PCR (Applied Biosystems) according to the manufacturer's instructions, in a 7300 System SDS Software v1.4.

Statistical analysis {#Sec16}
--------------------

The statistical analysis was performed using SPSS (IBM SPSS Statistics, version 19.0.0), except for the Hardy-Weinberg Equilibrium (HWE) for each polymorphism, determined in ARLEQUIN version 3.11 \[[@CR78]\]. Gender and SPT data among subgroups of asthma persistence and severity were analysed using Fisher's exact test, to account for the small sample size.

Following a Shapiro-Wilkoxon test of normality, the association analysis of FEV~1~ to asthma persistence and severity was performed using a t-test (normal distribution), while a Mann--Whitney test was used for FVC (due to its non-normal distribution). The analysis of FEV~1~ and FVC indexes among SNP genotypes was tested using ANOVA (with Bonferroni post-hoc correction) and Kruskal-Wallis test, respectively.

The association of SNP genotypes and alleles to asthma susceptibility and severity, for multiple genetic models, were assessed by χ^2^ (or Fisher's exact tests where appropriate) and corresponding odds ratio (OR) determined with a 95% CI. Haplotypes were generated with Haploview version 4.2 \[[@CR79]\] and their association with the disease was analysed with the hap-assoc option in PLINK \[[@CR80]\]. Epistatic interactions between pairs of SNPs were assessed with the PLINK option \--epistasis \--epi1 1. Permutation procedures were used to obtain significance levels empirically and results were interpreted at a significance level set for p \< 0.05.

The transmission disequilibrium test (TDT) was determined through a McNemar test \[[@CR81]\], based on data from heterozygous parents and the frequency of allelic transmission to affected offspring. The corresponding p-value (considered at a 0.05 significance level) and OR (95% CI) were determined.

To reduce the likelihood of commiting a Type I error due to multiple testing, the Benjamini & Hochberg procedure \[[@CR82]\] was adopted for each set of results (presented in distinct tables) to control the false discovery rate set at Q = 0.20.
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###### 

Additional file 1: **Skin prick tests positivity across asthma persistence and severity subgroups.** The table describes the qualitative (positive *vs.* negative) and quantitative (\<10 mm vs. ≥ 10 mm) reaction to common allergens in Madeira island (*Dermatophagoides pteronyssinus, Blomia tropicalis,* Storage mites, Mix fungi, Indoor fungi, cat and dog) across overall asthma and asthma severity categories (intermittent, persistent, mild and moderate-severe). (DOCX 106 KB)

###### 

Additional file 2: **SNP allelic frequencies for the Madeira reference set and asthmatics study population.** The table describes the allelic frequencies for SNPs *IL4-590, IL4-RP2, IL13-c.144, ADRB2-c.16, ADAM33-V4, ADAM33-S1c.710, GSDML-236, STAT6-21*) across the reference group, overall asthma and asthma severity categories (intermittent, persistent, mild and moderate-severe). (DOCX 96 KB)
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